Director/PDMR Shareholding

RNS Number : 1427V

Advanced Medical Solutions Grp PLC

04 April 2019

 

4 April 2019

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

            Director/PDMR and PCA Shareholding

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that it was notified on 1 April 2019 that on the same day, Chris Meredith, who is a Director and PDMR, had sold 5,735 Ordinary Shares of 5p held on his behalf in the name of Platform Securities Nominees Limited ("CM's Nominee") at a price of 318p per Ordinary Share. AMS was also notified that on 1 April 2019 that on the same day, Chris Meredith's PCA had sold 4,850 Ordinary Shares of 5p held on their behalf in the name of Platform Securities Nominees Limited ("PCA's Nominee") at a price of 318p per Ordinary Share.

On the same day, Chris Meredith purchased 5,735 Ordinary Shares of 5p through an Individual Savings Account held in his name at a price of 318.25p per Ordinary Share. The Company was also informed that at the same time an Individual Savings Account held in the name of Chris Meredith's PCA purchased 4,850 Ordinary Shares of 5p at a price of 318.25p per Ordinary Share. 

The number of shares, and the beneficial ownership of the shares, held by Chris Meredith and his PCA's remains unchanged. These transactions are part of normalised tax planning.

The transactions are summarised below:

Director	Number of Ordinary Shares sold from Nominee	Price per Ordinary Share sold	Number of Ordinary Shares purchased by an Individual Savings Account	Price paid per Ordinary Share by an Individual Savings Account	Number of Ordinary Shares purchased by an Individual Savings Account	Price paid per Ordinary Share by an Individual Savings Account
Chris Meredith	5,735	318p	5,735	318.25p	-	-
Chris Meredith	4,850	318p	-	-	4,850	318.25p

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Chris Meredith
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:   Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: ·        Sale of 5,735 Ordinary Shares of 5p held in the name of CM's Nominee ·        Purchase of 5,735 Ordinary Shares of 5p by an Individual Savings Account held in the name of Chris Meredith
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) Sale of shares from CM's Nominee holding at 318p per share 5,735 Purchase by an Individual Savings Account at 318.25p per share 5,735
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: 5,735 Aggregated price: 318p
e)	Date of the transaction: 01/04/2019
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

1.	Details of the person discharging managerial responsibilities/person closely associated
a)	Name: Chris Meredith
2.	Reason for the notification
a)	Position/status: Director/PDMR
b)	Initial notification/Amendment: Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name:   Advanced Medical Solutions Group plc
b)	LEI: 213800HJP6OWOSZI1L74
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594
b)	Nature of the transactions: ·        Sale of 4,850 Ordinary Shares of 5p held in the name of the PCA's Nominee ·        Purchase of 4,850 Ordinary Shares of 5p into an Individual Savings Account held in the name of Chris Meredith's PCA
c)	Price(s) and volume(s): Sale of shares: Price(s) Volume(s) Sale of shares from PCA's Nominee holding at 318p per share 4,850 Purchase by an Individual Savings Account at 318.25p per share 4,850
d)	Aggregated information: (Relates to those shares sold only) Aggregated volume: 4,850 Aggregated price: 318p
e)	Date of the transaction: 01/04/2018
f)	Place of the transaction: London Stock Exchange, AIM Market (XLON)

- End -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott / Matthew Neal / Nicholas Brown / Olivia Manser	[e-mail]
Investec Bank PLC (NOMAD & Broker)	Tel: [phone]
Daniel Adams / Gary Clarence / Patrick Robb

About Advanced Medical Solutions Group plc - see www.admedsol.com

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include tissue adhesives, sutures, biosurgical devices, internal sealants, silver alginates, alginates and foams, which it markets under its brands; LiquiBand®, LiquiBand® Fix 8™, RESORBA® and ActivHeal® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.  Established in 1991, the Group has approximately 630 employees.  For more information, please see www.admedsol.com.

 

END

 

 

DSHGCGDSXBGBGCS